invios-Logo-RGB-small.jpg
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
18 avr. 2023 09h00 HE | invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
invios-Logo-RGB-small.jpg
invIOs to present at Biotech Showcase
14 déc. 2022 08h00 HE | invIOs GmbH
VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...
invios-Logo-RGB-small.jpg
invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
10 nov. 2022 09h40 HE | invIOs GmbH
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...
invios-Logo-RGB-small.jpg
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
03 nov. 2022 03h00 HE | invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...
invios-Logo-CMYK-300DPI.jpg
invIOs to present data from clinical stage Cbl-b program at SITC 2022
18 oct. 2022 02h00 HE | invIOs GmbH
VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its...
invios-Logo-CMYK-300DPI.jpg
invIOs to present at upcoming industry and investor conferences
11 oct. 2022 02h00 HE | invIOs GmbH
VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three...
invios-Logo-CMYK-300DPI.jpg
APEIRON shareholders approve new group structure geared towards enabling innovation and growth
26 avr. 2022 02h00 HE | invIOs GmbH
VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) -- APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of...
invios-Logo-CMYK-300DPI.jpg
invIOs to present at upcoming conferences
03 févr. 2022 02h00 HE | invIOs GmbH
VIENNA, Austria, Feb. 03, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming...
invios-Logo-CMYK-300DPI.jpg
invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline
16 déc. 2021 02h00 HE | invIOs GmbH
VIENNA, Austria, Dec. 16, 2021 (GLOBE NEWSWIRE) -- invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it...